CELLECT BIOTECH/S (NASDAQ:APOP) shares fell 0.4% during mid-day trading on Friday . The stock traded as low as $2.26 and last traded at $2.32, 44,338 shares were traded during mid-day trading. A decline of 93% from the average session volume of 652,198 shares. The stock had previously closed at $2.33.

The firm has a 50 day moving average price of $2.58 and a 200-day moving average price of $1.67. The company has a current ratio of 6.50, a quick ratio of 6.50 and a debt-to-equity ratio of 0.04. The firm has a market cap of $5.24 million, a PE ratio of -1.00 and a beta of 1.74.

CELLECT BIOTECH/S (NASDAQ:APOP) last announced its quarterly earnings data on Tuesday, November 19th. The company reported ($0.61) earnings per share (EPS) for the quarter.

An institutional investor recently raised its position in CELLECT BIOTECH/S stock. Wedbush Securities Inc. grew its stake in CELLECT BIOTECH/S (NASDAQ:APOP) by 43.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 165,500 shares of the company’s stock after buying an additional 50,000 shares during the quarter. Wedbush Securities Inc. owned 1.48% of CELLECT BIOTECH/S worth $81,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 25.48% of the company’s stock.


Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Further Reading: Asset Allocation, Balancing Your Investments

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.